Candel Therapeutics (CADL) Retained Earnings (2020 - 2025)
Candel Therapeutics recorded quarterly Retained Earnings of -$230.4 million in Q4 2025, down 14.68% quarter-over-quarter from -$200.9 million in Q3 2025, and down 19.87% year-over-year from -$287.5 million in Q4 2024.
Candel Therapeutics' Retained Earnings history runs 6 years deep, the most recent figure standing at -$230.4 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 19.87% year-over-year to -$230.4 million; the TTM figure through Dec 2025 stood at -$230.4 million (down 19.87% YoY), while the FY2025 annual figure was -$230.4 million, down 19.87% from the prior year.
- Retained Earnings came in at -$230.4 million for Q4 2025 at Candel Therapeutics, down from -$200.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$65.7 million in Q2 2021 to a low of -$230.4 million in Q4 2025.
- A 5-year average of -$135.0 million and a median of -$125.9 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings plunged 81.78% in 2021 and decreased 12.78% in 2025, its largest moves.
- Candel Therapeutics' Retained Earnings stood at -$80.3 million in 2021, then declined by 23.41% to -$99.1 million in 2022, then sank by 38.29% to -$137.0 million in 2023, then plunged by 40.27% to -$192.2 million in 2024, then retreated by 19.87% to -$230.4 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$230.4 million, -$200.9 million, and -$189.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | -230.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -230.40 Mn |
| Sep 30, 2025 | -200.90 Mn |
| Jun 30, 2025 | -189.60 Mn |
| Mar 31, 2025 | -184.83 Mn |
| Dec 31, 2024 | -192.21 Mn |
| Sep 30, 2024 | -178.13 Mn |
| Jun 30, 2024 | -167.49 Mn |
| Mar 31, 2024 | -145.25 Mn |
| Dec 31, 2023 | -137.03 Mn |
| Sep 30, 2023 | -125.90 Mn |
| Jun 30, 2023 | -117.50 Mn |
| Mar 31, 2023 | -107.90 Mn |
| Dec 31, 2022 | -99.09 Mn |
| Sep 30, 2022 | -94.01 Mn |
| Jun 30, 2022 | -85.32 Mn |
| Mar 31, 2022 | -81.17 Mn |
| Dec 31, 2021 | -80.30 Mn |
| Sep 30, 2021 | -81.89 Mn |
| Jun 30, 2021 | -65.73 Mn |
| Dec 31, 2020 | -44.17 Mn |